In addition, we investigated the potential link between genetic alterations in DYRK2 and clinical survival prognosis in different cancer types.For example, the data of Fig. 3D indicate that UCEC cases with altered DYRK2 showed poor prognosis in progression-free (P = 0.013),but not disease free(P = 0.0618),overall (P = 0.148) and disease-specific (P = 0.159) survival, compared with cases without DYRK2 alteration.In hepatocellular carcinoma, altered DYRK2 showed poorer prognosis in progression-free (P = 3.795e−3) and disease free(P = 1.626e−3) survival. This evidence concerns the gene DYRK2 and cancer.